Heffter Research Institute | Easing Cancer-Related Anxiety.
Heffter’s research demonstrates emotional relief through supervised psilocybin treatments, with Phase 2 results and ongoing trials at Usona.
citydifferentinvestments.comCrawled Oct 31, 2026
Heffter’s research demonstrates emotional relief through supervised psilocybin treatments, with Phase 2 results and ongoing trials at Usona.
Neuroscience studies funded and supported by the Heffter Research Institute focus on how psilocybin affects mood and related attitudes. This psilocybin research has the potential to lead to breakthroughs in understanding neurobiology.
Heffter Institute explores psilocybin's promise for addiction treatment. Potential relief for cigarettes, cocaine, alcohol dependence.
Heffter scientists will be speaking at this conference, in Madison, WI on April 28-29, 2011: OVERVIEW: The over-arching theme of this Forum’s is exploration of the Mind-Brain phenomenon and how this relates to human consciousness. The challenge faced by planners of Manifesting the Mind was...
The 2012 Bioethics Forum in Madison, Wisconsin, featured expert speakers discussing topics in bioethics.
Lame puns aside Alexander Zaitchik extensive article on psychedelics in SALON is a fine overview concerning their history and present medical status. Prominently featured are Heffter researchers, Dr. Stephen Ross, Dr. Roland Griffiths and Dr. Charles Grob.
Heffter Research Institute celebrated its 30th anniversary in 2023 and lists 156 funded research projects. As of 2020, Heffter-affiliated researchers authored 63% of the top-cited articles on classic psychedelics.
The complete 2011 presentations of speakers at MANIFESTING THE MIND in Madison Wisconsin are now available on-line. Please follow the link and enjoy an incredible array of speakers discussingconsciousness and the neurology involved in the process.
Dr. Stephen Ross, a Heffter board member, wrote about the medical community’s reluctance to address death and its impact on patients.
ABC News and the Associated Press reported on Nicky Edlich’s psilocybin treatment at New York University in 2010.
CNN interviewed Dr. Stephen Ross and Dr. Sanjay Gupta about the benefits of psilocybin research in 2010.
The New York Times featured Dr. Clark Martin, whose depression improved during Heffter-supported research. Dr. Roland Griffiths led a Johns Hopkins study on psilocybin’s effects.
Dr. Roland Griffiths presented research at TEDx MidAtlantic showing psilocybin’s potential to induce meaningful mystical experiences.
Scienceline published Pam Sakuda’s account of psychedelic treatment in a research study in 2010.
Psilocybin research conducted by Dr. Roland Griffiths at the Johns Hopkins University School of Medicine has been featured in TIME magazine. Please follow the link. https://healthland.time.com/2011/06/16/magic-mushrooms-can-improve-psychological-health-long-term/#more-36198
The Heffter Research Institute awarded its Lifetime Achievement Award to Dr. Stanislav Grof in 2011.
The Heffter Research Institute was founded in 1993 to study the medical potential of psychedelics.
Dr. Grob is currently Professor of Psychiatry and Pediatrics at the UCLA School of Medicine and the Director of the Division of Child and Adolescent Psychiatry at the Harbor-UCLA Medical Center.
Katrin Preller earned her PhD from the University of Zurich, researching the long-term effects of cocaine, MDMA, and heroin use.
Steven Grant, Ph.D., joined the Heffter Research Institute in 2021 after nearly 5 decades of conducting basic and clinical research on the action of drugs on the brain.
Heffter research has shown psilocybin can relieve the symptoms of anxiety and depression often found in patients with a cancer diagnosis.
Heffter Research Institute psilocybin studies reveal the potential for reducing psychological distress. Psilocybin may also contribute to spiritual practices and improving overall wellbeing.
Heffter Research Institute lists active studies recruiting participants for psilocybin research at Johns Hopkins, NYU, and the University of Alabama.
Heffter Institute advances psilocybin research for cancer distress, addiction. Sole US supporter, major European funder for 20+ years.